{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:33:26Z","timestamp":1779917606663,"version":"3.53.1"},"reference-count":248,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biology"],"abstract":"<jats:p>Background and aim: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare multisystem autoimmune disease developed by autoantibody production against human neutrophilic granulocytes, including proteinase-3 (PR3) and myeloperoxidase (MPO). The management of AAV patients is difficult due to the multiorgan involvement, high rate of relapse, and complications of immunosuppressive agents that make it challenging. This study aims to investigate the efficacy and safety of rituximab (RTX) therapy in patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) subtypes. Method: The PubMed\/Medline database was searched for any studies related to RTX therapy in ANCA-associated vasculitis (GPA and MPA subtypes), from inception to 1 August 2022, and proceeded in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Results: Our search resulted in 1082 initial records. After the elimination of review papers, irrelevant studies, and non-English records, 223 articles were included, and the data related to the efficacy and safety of RTX therapy were extracted. Several randomized and non-randomized studies showed that RTX is an effective treatment option for patients with AAV. Most of the studies showed the very effective effect of RTX in controlling disease in AAV patients, including pediatrics, adults, and elderlies, although RTX cannot completely prevent relapse. However, maintenance therapy helps delay the disease\u2019s relapse and causes sustained remission. Not only the licensed dose (375 mg\/m2 intravenous per week for 4 weeks) could induce disease remission, but studies also showed that a single infusion of RTX could be effective. Although RTX could resolve many rare manifestations in AAV patients, there are few reports showing treatment failure. Additionally, few sudies have reported the unexpeted worsening of the disease after RTX administration. Generally, RTX is relatively safe compared to conventional therapies, but some serious adverse effects, mainly infections, cytopenia, hypogammaglobinemia, malignancy, and hypersensitivity have been reported. Conclusions: RTX is an effective and relatively safe therapeutic option for AAV. Studies on the evaluation of the safety profiles of RTX and the prevention of severe RTX-related side effects in AAV patients are required.<\/jats:p>","DOI":"10.3390\/biology11121767","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T02:18:48Z","timestamp":1670379528000},"page":"1767","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-6925","authenticated-orcid":false,"given":"Mohammad Amin","family":"Habibi","sequence":"first","affiliation":[{"name":"Clinical Research Development Center, Qom University of Medical Sciences, Qom 3719964797, Iran"},{"name":"Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran P.O. Box 982166757001, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Alesaeidi","sequence":"additional","affiliation":[{"name":"Rheumatology Research Center, Tehran University of Medical Sciences, Tehran P.O. Box 982188220065, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohadeseh","family":"Zahedi","sequence":"additional","affiliation":[{"name":"Clinical Research Development Center, Qom University of Medical Sciences, Qom 3719964797, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samin","family":"Hakimi Rahmani","sequence":"additional","affiliation":[{"name":"Clinical Research Development Center, Qom University of Medical Sciences, Qom 3719964797, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mohammad","family":"Piri","sequence":"additional","affiliation":[{"name":"Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran P.O. Box 982166757001, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheil","family":"Tavakolpour","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","article-title":"ANCA-associated vasculitis","volume":"6","author":"Kitching","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"i14","DOI":"10.1093\/ndt\/gfv022","article-title":"Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"30","author":"Watts","year":"2015","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"60","DOI":"10.7861\/clinmedicine.17-1-60","article-title":"ANCA-associated vasculitis","volume":"17","author":"Yates","year":"2017","journal-title":"Clin. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2013-203927","article-title":"Damage in the anca-associated vasculitides: Long-term data from the European vasculitis study group (EUVAS) therapeutic trials","volume":"74","author":"Robson","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1681\/ASN.V82314","article-title":"ANCA small-vessel vasculitis","volume":"8","author":"Falk","year":"1997","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1681\/ASN.2014090903","article-title":"Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis","volume":"26","author":"Hilhorst","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3892\/etm.2021.9993","article-title":"Differences between myeloperoxidase-antineutrophil cytoplasmic autoantibody (ANCA) and proteinase 3-ANCA associated vasculitis: A retrospective study from a single center in China","volume":"21","author":"Wu","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MD.0b013e31817c744b","article-title":"Antineutrophil cytoplasmic autoantibody-associated vasculitis in older patients","volume":"87","author":"Chen","year":"2008","journal-title":"Medicine"},{"key":"ref_10","first-page":"51","article-title":"Interstitial Lung Disease with ANCA-associated Vasculitis","volume":"9","author":"Katsumata","year":"2015","journal-title":"Clin. Med. Insights Circ. Respir. Pulm. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrneph.2013.225","article-title":"Treatment of ANCA-associated vasculitis","volume":"10","author":"Gross","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1002\/art.34547","article-title":"Brief Report: Long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Faurschou","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11926-017-0632-1","article-title":"Rituximab in ANCA-Associated Vasculitis","volume":"19","author":"Hassan","year":"2017","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., G\u00f8tzsche, P.C., Ioannidis, J.P., Clarke, M., Devereaux, P.J., Kleijnen, J., and Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med., 6.","DOI":"10.2427\/5768"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ejim.2015.04.022","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management","volume":"26","author":"Groh","year":"2015","journal-title":"Eur. J. Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: Reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/annrheumdis-2014-206404","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial","volume":"74","author":"Jones","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1681\/ASN.2014010046","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement","volume":"26","author":"Geetha","year":"2015","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13063-017-1857-z","article-title":"Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): Study protocol for a randomized controlled trial","volume":"18","author":"Gopaluni","year":"2017","journal-title":"Trials"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.semarthrit.2018.01.013","article-title":"Reducing glucocorticoid duration in ANCA-associated vasculitis: A pilot trial","volume":"48","author":"Miloslavsky","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_25","first-page":"S54","article-title":"Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: Impact on global disability and health-related quality of life","volume":"34","author":"Pugnet","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides","volume":"77","author":"Terrier","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: Results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/M19-3827","article-title":"Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial","volume":"173","author":"Charles","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1164\/rccm.200507-1144OC","article-title":"Rituximab for refractory Wegener\u2019s granulomatosis: Report of a prospective, open-label pilot trial","volume":"173","author":"Keogh","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/rheumatology\/kel098","article-title":"Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab","volume":"45","author":"Stasi","year":"2006","journal-title":"Rheumatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3109\/14397595.2014.981945","article-title":"Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis","volume":"25","author":"Nagafuchi","year":"2015","journal-title":"Mod. Rheumatol."},{"key":"ref_33","first-page":"468","article-title":"Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases","volume":"28","author":"Callejas","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s10067-011-1756-8","article-title":"Long-term follow-up of different refractory systemic vasculitides treated with rituximab","volume":"30","author":"Rees","year":"2011","journal-title":"Clin. Rheumatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ndt\/gfn430","article-title":"Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: A single-centre experience with 15 patients","volume":"24","author":"Lovric","year":"2009","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2169\/internalmedicine.46.6156","article-title":"Two cases of refractory Wegener\u2019s granulomatosis successfully treated with rituximab","volume":"46","author":"Tamura","year":"2007","journal-title":"Intern. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/rheumatology\/key117","article-title":"Rituximab for induction and maintenance therapy of granulomatosis with polyangiitis: A single-centre cohort study on 114 patients","volume":"58","author":"Iudici","year":"2019","journal-title":"Rheumatology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3899\/jrheum.120482","article-title":"Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: Results from a German registry (GRAID)","volume":"39","author":"Roll","year":"2012","journal-title":"J. Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10067-013-2351-y","article-title":"Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis\u2014A case series","volume":"33","author":"Knight","year":"2014","journal-title":"Clin. Rheumatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.38788","article-title":"Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"66","author":"Miloslavsky","year":"2014","journal-title":"Arthritis Rheum."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3109\/03009742.2011.620573","article-title":"Rituximab in relapsing or refractory ANCA-associated vasculitis: A case series of 16 patients","volume":"41","author":"Wendt","year":"2012","journal-title":"Scand. J. Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2215\/CJN.08821209","article-title":"Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"5","author":"Rhee","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s10067-020-05261-7","article-title":"Experience with similar biologic rituximab in 77 patients of granulomatosis with polyangiitis-a real-life experience","volume":"40","author":"Mittal","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1002\/art.34583","article-title":"Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Smith","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3899\/jrheum.110143","article-title":"Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis","volume":"39","author":"Pagnoux","year":"2012","journal-title":"J. Rheumatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W","article-title":"Response of Wegener\u2019s granulomatosis to anti-CD20 chimeric monoclonal antibody therapy","volume":"44","author":"Specks","year":"2001","journal-title":"Arthritis Rheum."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"c92","DOI":"10.1159\/000083426","article-title":"Rituximab induced remission in a patient with Wegener\u2019s granulomatosis","volume":"99","author":"Kallenbach","year":"2005","journal-title":"Nephron. Clin. Pract."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"381","DOI":"10.20452\/pamw.424","article-title":"Wegener\u2019s granulomatosis effectively treated with rituximab: A case study","volume":"118","author":"Kowalewska","year":"2008","journal-title":"Pol. Arch. Med. Wewn."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1007\/s00417-015-3198-5","article-title":"Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener\u2019s)","volume":"253","year":"2015","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1080\/09273948.2017.1327602","article-title":"Rituximab Induction and Maintenance Treatment in Patients with Scleritis and Granulomatosis with Polyangiitis (Wegener\u2019s)","volume":"26","author":"You","year":"2018","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1136\/bjo.2005.075689","article-title":"Successful treatment of Wegener\u2019s granulomatosis associated scleritis with rituximab","volume":"89","author":"Cheung","year":"2005","journal-title":"Br. J. Ophthalmol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000486791","article-title":"Cyclophosphamide or Rituximab Treatment of Scleritis and Uveitis for Patients with Granulomatosis with Polyangiitis","volume":"61","author":"Ahmed","year":"2019","journal-title":"Ophthalmic. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"101333","DOI":"10.1016\/j.ajoc.2022.101333","article-title":"Posterior scleritis with anti-neutrophil cytoplasmic antibody-associated vasculitis utilizing rituximab therapy to maintain remission: A case report","volume":"25","author":"Weng","year":"2022","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.22336\/rjo.2021.19","article-title":"Wegener\u2019s granulomatosis with orbital involvement: Case report and literature review","volume":"65","author":"Ioana","year":"2021","journal-title":"Rom. J. Ophthalmol."},{"key":"ref_55","first-page":"566","article-title":"Refractory Wegener\u2019s granulomatosis: Effect of rituximab on granulomatous bilateral orbital involvement","volume":"11","author":"Avshovich","year":"2009","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/s10165-011-0507-7","article-title":"Rituximab as a new therapeutic option in granulomatosis with polyangiitis: A report of two cases","volume":"22","author":"Dalkilic","year":"2012","journal-title":"Mod. Rheumatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"bcr2012007518","DOI":"10.1136\/bcr-2012-007518","article-title":"Rituximab seems a promising therapeutic option in granulomatosis with polyangiitis with intestinal perforation: A case report and literature review","volume":"2013","author":"Dag","year":"2013","journal-title":"BMJ Case Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/01.rhu.0000191217.11688.3c","article-title":"Wegener granulomatosis with massive intracerebral hemorrhage: Remission of disease in response to rituximab","volume":"11","author":"Memet","year":"2005","journal-title":"J. Clin. Rheumatol."},{"key":"ref_59","first-page":"900","article-title":"Refractory Wegener\u2019s meningitis treated with rituximab","volume":"34","author":"Bawa","year":"2007","journal-title":"J. Rheumatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4081\/reumatismo.2013.90","article-title":"Granulomatosis polyangiitis associated with meningeal involvement: Response to rituximab therapy after failure of cyclophosphamide","volume":"65","author":"Benucci","year":"2013","journal-title":"Reumatismo"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/bjo.2006.113316","article-title":"Rituximab treatment for peripheral ulcerative keratitis associated with Wegener\u2019s granulomatosis","volume":"91","author":"Freidlin","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1097\/ICO.0000000000000919","article-title":"Successful Treatment Strategies in Granulomatosis With Polyangiitis-Associated Peripheral Ulcerative Keratitis","volume":"35","author":"Ebrahimiadib","year":"2016","journal-title":"Cornea"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"An, J., and Song, J.W. (2021). Life-Threatening Subglottic Stenosis of Granulomatosis with Polyangiitis: A Case Report. Medicina, 57.","DOI":"10.3390\/medicina57050423"},{"key":"ref_64","first-page":"S23","article-title":"Adjunction of rituximab to steroids and immunosuppressants for refractory\/relapsing Wegener\u2019s granulomatosis: A study on 8 patients","volume":"25","author":"Brihaye","year":"2007","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/RHU.0b013e31816b4487","article-title":"Effect of rituximab on refractory Wegener granulomatosis with predominant granulomatous disease","volume":"14","year":"2008","journal-title":"J. Clin. Rheumatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/ndt\/gfh599","article-title":"Effective therapeutic use of rituximab in refractory Wegener\u2019s granulomatosis","volume":"20","author":"Ferraro","year":"2005","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/ndt\/gfh852","article-title":"Rituximab is an alternative in a case of contra-indication of cyclophosphamide in Wegener\u2019s granulomatosis","volume":"20","author":"Bachmeyer","year":"2005","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_68","first-page":"2017","article-title":"Efficacy of rituximab in limited Wegener\u2019s granulomatosis with refractory granulomatous manifestations","volume":"35","author":"Seo","year":"2008","journal-title":"J. Rheumatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/02813430510015269","article-title":"Anti-CD20 therapy of treatment-resistant Wegener\u2019s granulomatosis: Favourable but temporary response","volume":"34","author":"Omdal","year":"2005","journal-title":"Scand. J. Rheumatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/ard.2005.044420","article-title":"Lack of efficacy of rituximab in Wegener\u2019s granulomatosis with refractory granulomatous manifestations","volume":"65","author":"Aries","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2174\/1874306400903010094","article-title":"Effectiveness of rituximab in severe Wegener\u2019s granulomatosis: Report of two cases and review of the literature","volume":"3","author":"Oristrell","year":"2009","journal-title":"Open Respir. Med. J."},{"key":"ref_72","first-page":"S103","article-title":"Sustained 3-year remission after rituximab treatment in a patient with refractory Wegener\u2019s granulomatosis","volume":"24","author":"Tektonidou","year":"2006","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00296-010-1462-x","article-title":"Rituximab and leflunomide for Wegener\u2019s granulomatosis: A long-term follow-up","volume":"31","author":"Henes","year":"2011","journal-title":"Rheumatol. Int."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/RHU.0b013e3181886064","article-title":"Rituximab for severe refractory pediatric Wegener granulomatosis","volume":"14","author":"Patel","year":"2008","journal-title":"J. Clin. Rheumatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00467-016-3559-2","article-title":"Paediatric anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: An update on renal management","volume":"33","author":"Plumb","year":"2018","journal-title":"Pediatr. Nephrol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"322","DOI":"10.5414\/CNP68322","article-title":"Successful therapeutic use of rituximab in refractory Wegener\u2019s granulomatosis after renal transplantation","volume":"68","author":"Hermle","year":"2007","journal-title":"Clin. Nephrol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"846063","DOI":"10.1155\/2010\/846063","article-title":"Successful Treatment of ANCA-Negative Wegener\u2019s Granulomatosis with Rituximab","volume":"2010","author":"Khan","year":"2010","journal-title":"Int. J. Rheumatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/s10165-008-0119-z","article-title":"Treatment of refractory retrobulbar granuloma with rituximab in a patient with ANCA-negative Wegener\u2019s granulomatosis: A case report","volume":"19","author":"Ooka","year":"2009","journal-title":"Mod. Rheumatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/mrcr\/rxab034","article-title":"Successful rituximab treatment in a patient with ANCA-negative granulomatosis with polyangitis: A case report","volume":"6","author":"Kimura","year":"2022","journal-title":"Mod. Rheumatol. Case Rep"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/RHU.0b013e31816b2fbd","article-title":"ANCA vasculitis in the elderly","volume":"14","author":"Hoganson","year":"2008","journal-title":"J. Clin. Rheumatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fped.2018.00226","article-title":"Primary Vasculitis in Childhood: GPA and MPA in Childhood","volume":"6","author":"Jariwala","year":"2018","journal-title":"Front. Pediatr."},{"key":"ref_82","first-page":"e24470","article-title":"Disease Severity and Response to Induction Therapy in Hispanic Patients With Antineutrophilic Cytoplasmic Autoantibody-Associated Vasculitis-Related Diffuse Alveolar Hemorrhage","volume":"14","author":"Loftis","year":"2022","journal-title":"Cureus"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.semarthrit.2015.02.005","article-title":"Rituximab for remission induction in elderly patients with ANCA-associated vasculitis","volume":"45","author":"Timlin","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/art.41901","article-title":"Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis","volume":"74","author":"Brogan","year":"2022","journal-title":"Arthritis Rheum."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1159\/000503318","article-title":"Sequential Therapy for Remission Induction in Severe Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis","volume":"50","author":"Kant","year":"2019","journal-title":"Am. J. Nephrol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1002\/art.24637","article-title":"A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"60","author":"Jones","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_87","first-page":"663","article-title":"Lower doses of rituximab in remission induction for refractory granulomatosis with polyangiitis","volume":"71","author":"Zugaj","year":"2014","journal-title":"Przegl. Lek."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1620\/tjem.242.53","article-title":"Remission Induction Therapy with Rituximab for Microscopic Polyangiitis: A Feasibility Study","volume":"242","author":"Saito","year":"2017","journal-title":"Tohoku J. Exp. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3109\/03009742.2014.918172","article-title":"Single-dose rituximab for remission induction and maintenance therapy in ANCA-associated vasculitis: A retrospective analysis of 17 patients","volume":"43","author":"Moog","year":"2014","journal-title":"Scand. J. Rheumatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1136\/annrheumdis-2014-206496","article-title":"Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: Identifying B cell biomarkers for relapse to guide retreatment decisions","volume":"74","author":"Vital","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_91","first-page":"i123","article-title":"Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"30","author":"McGregor","year":"2015","journal-title":"Nephrol. Dial. Transpl. Off. Publ. Eur. Dial. Transpl. Assoc.\u2013Eur. Ren. Assoc."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/art.20718","article-title":"Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"Keogh","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"52072","DOI":"10.18632\/oncotarget.18120","article-title":"The \u201c4 plus 2\u201d rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study","volume":"8","author":"Roccatello","year":"2017","journal-title":"Oncotarget"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"88","DOI":"10.5152\/eurjrheum.2022.21063","article-title":"A comparison of rituximab with cyclophosphamide in terms of efficacy and complications as induction therapy for treating granulomatosis with polyangiitis: A three-center study","volume":"9","author":"Chaleshtori","year":"2022","journal-title":"Eur. J. Rheumatol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Morel, P., Karras, A., Porcher, R., Belenfant, X., Audard, V., Rafat, C., Hanouna, G., Beaudreuil, S., Vilain, C., and Hummel, A. (2022). Management of severe renal disease in anti-neutrophil-cytoplasmic-antibody-associated vasculitis: Place of rituximab and plasma exchange?. Rheumatology.","DOI":"10.1093\/rheumatology\/keac046"},{"key":"ref_96","first-page":"4808806","article-title":"Management and Outcomes of ANCA-Associated Vasculitis at a Tertiary Healthcare Facility","volume":"2022","author":"Moollan","year":"2022","journal-title":"Autoimmune. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nrrheum.2010.150","article-title":"Rituximab has similar short-term safety and efficacy to cyclophosphamide in ANCA-associated vasculitis","volume":"6","author":"Nanda","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1681\/ASN.2019111197","article-title":"Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease","volume":"31","author":"Irazabal","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_99","first-page":"S63","article-title":"Infliximab or rituximab for refractory Wegener\u2019s granulomatosis: Long-term follow up. A prospective randomised multicentre study on 17 patients","volume":"29","author":"Cohen","year":"2011","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/rheumatology\/ket381","article-title":"Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: A multicentre retrospective study on 80 patients","volume":"53","author":"Charles","year":"2014","journal-title":"Rheumatology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1002\/art.34584","article-title":"Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener\u2019s): Ten-year experience at a single center","volume":"64","author":"Golbin","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/art.41551","article-title":"Sustained Remission of Granulomatosis With Polyangiitis After Discontinuation of Glucocorticoids and Immunosuppressant Therapy: Data From the French Vasculitis Study Group Registry","volume":"73","author":"Iudici","year":"2021","journal-title":"Arthritis Rheum."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaut.2014.03.002","article-title":"Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener\u2019s). Results of a single-center cohort study on 66 patients","volume":"50","author":"Calich","year":"2014","journal-title":"J. Autoimmun."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1093\/rheumatology\/kez621","article-title":"Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: Randomized-trial post-hoc analysis","volume":"59","author":"Charles","year":"2020","journal-title":"Rheumatology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1080\/14397595.2020.1790778","article-title":"Rituximab maintenance therapy for patients with antineutrophil cytoplasmic antibody-associated vasculitis in Japan","volume":"31","author":"Takeyama","year":"2021","journal-title":"Mod. Rheumatol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/rheumatology\/ket257","article-title":"Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: Results from a single centre","volume":"52","author":"Besada","year":"2013","journal-title":"Rheumatology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1136\/annrheumdis-2019-216863","article-title":"Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis","volume":"79","author":"Smith","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40620-015-0208-y","article-title":"Rituximab for treatment of severe renal disease in ANCA associated vasculitis","volume":"29","author":"Geetha","year":"2016","journal-title":"J. Nephrol."},{"key":"ref_109","first-page":"260","article-title":"A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"58","author":"Pepper","year":"2019","journal-title":"Rheumatology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/08916934.2014.914174","article-title":"Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease","volume":"47","author":"Venhoff","year":"2014","journal-title":"Autoimmunity"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1093\/rheumatology\/keab791","article-title":"Rituximab plus methotrexate combination as a salvage therapy in persistently active granulomatosis with polyangiitis","volume":"61","author":"Sorin","year":"2022","journal-title":"Rheumatology"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/art.38744","article-title":"Rituximab with or without a conventional maintenance agent in the treatment of relapsing granulomatosis with polyangiitis (Wegener\u2019s): A retrospective single-center study","volume":"66","author":"Azar","year":"2014","journal-title":"Arthritis Rheum."},{"key":"ref_113","first-page":"155","article-title":"Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis","volume":"35","author":"Lionaki","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.kint.2021.08.025","article-title":"Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis","volume":"100","author":"Gulati","year":"2021","journal-title":"Kidney Int."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Rymarz, A., Matyjek, A., Su\u0142ek-Jak\u00f3bczyk, M., Mosakowska, M., and Niemczyk, S. (2021). Impaired Kidney Function Associated with Increased Risk of Side Effects in Patients with Small Vessel Vasculitis Treated with Rituximab as an Induction Therapy. J. Clin. Med., 10.","DOI":"10.3390\/jcm10040786"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","article-title":"Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type","volume":"75","author":"Unizony","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/art.39104","article-title":"Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids","volume":"67","author":"Miloslavsky","year":"2015","journal-title":"Arthritis Rheum."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/ard.2011.153601","article-title":"Rituximab for refractory granulomatosis with polyangiitis (Wegener\u2019s granulomatosis): Comparison of efficacy in granulomatous versus vasculitic manifestations","volume":"71","author":"Holle","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/acr.22311","article-title":"Effectiveness of rituximab for the otolaryngologic manifestations of granulomatosis with polyangiitis (Wegener\u2019s)","volume":"66","author":"Lally","year":"2014","journal-title":"Arthritis Care Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/0194599813509784","article-title":"Otolaryngological progression of granulomatosis with polyangiitis after systemic treatment with rituximab","volume":"150","author":"Malm","year":"2014","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"ref_121","first-page":"1613","article-title":"Rituximab for refractory granulomatous eye disease","volume":"6","author":"Lower","year":"2012","journal-title":"Clin. Ophthalmol."},{"key":"ref_122","first-page":"S7","article-title":"Treatment of orbital inflammation with rituximab in Wegener\u2019s granulomatosis","volume":"30","author":"Baslund","year":"2012","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3899\/jrheum.130206","article-title":"Experiences with rituximab for the treatment of autoimmune diseases with ocular involvement","volume":"41","author":"Pelegrin","year":"2014","journal-title":"J. Rheumatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1749-4486.2009.01968.x","article-title":"B-cell depletion with rituximab for refractory head and neck Wegener\u2019s granulomatosis: A cohort study","volume":"34","author":"Chaudhry","year":"2009","journal-title":"Clin. Otolaryngol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1093\/rheumatology\/kez071","article-title":"Orbital mass in ANCA-associated vasculitides: Data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patients","volume":"58","author":"Durel","year":"2019","journal-title":"Rheumatology"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24454","article-title":"Rituximab is effective in the treatment of refractory ophthalmic Wegener\u2019s granulomatosis","volume":"60","author":"Taylor","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.autrev.2019.03.001","article-title":"Ocular involvement in granulomatosis with polyangiitis: A single-center cohort study on 63 patients","volume":"18","author":"Charles","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.ophtha.2015.01.016","article-title":"Long-term Outcomes of Rituximab Therapy in Ocular Granulomatosis with Polyangiitis: Impact on Localized and Nonlocalized Disease","volume":"122","author":"Joshi","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2215\/CJN.08290813","article-title":"Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure","volume":"9","author":"Lee","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000431336","article-title":"Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab","volume":"41","author":"Shah","year":"2015","journal-title":"Am. J. Nephrol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"99","DOI":"10.22265\/acnef.4.1.234","article-title":"Renal compromise in a patient with Wegener\u2019s granulomatosis: Clinical case and literature review","volume":"4","author":"Fabris","year":"2017","journal-title":"Rev. Colomb. Nefrol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"777134","DOI":"10.3389\/fimmu.2022.777134","article-title":"Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy","volume":"13","author":"Roccatello","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-3083.2012.02747.x","article-title":"Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: Long-term follow-up from a single centre","volume":"76","author":"Pullerits","year":"2012","journal-title":"Scand. J. Immunol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2796.2005.01494.x","article-title":"Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab","volume":"257","author":"Eriksson","year":"2005","journal-title":"J. Intern. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00296-018-3928-1","article-title":"Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: Experience of a single center and systematic review of non-randomized studies","volume":"38","author":"Ayan","year":"2018","journal-title":"Rheumatol. Int."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000329535","article-title":"Long-term effects of rituximab added to cyclophosphamide in refractory patients with vasculitis","volume":"34","author":"Roccatello","year":"2011","journal-title":"Am. J. Nephrol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10067-014-2816-7","article-title":"Rituximab use in patients with ANCA-associated vasculitis: Clinical efficacy and impact on immunological parameters","volume":"34","author":"Chocova","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1093\/ndt\/gfr127","article-title":"Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis","volume":"26","author":"Mansfield","year":"2011","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/ndt\/gfx378","article-title":"Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"34","author":"McAdoo","year":"2019","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Caroti, L., Cirami, C.L., Di Maria, L., Larti, A., Carta, P., Dervishi, E., Farsetti, S., Tsalouchos, A., Novelli, L., and Minetti, E.E. (2019). Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: A case series. BMC Nephrol., 20.","DOI":"10.1186\/s12882-019-1350-x"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e24028","DOI":"10.1097\/MD.0000000000024028","article-title":"Granulomatosis with polyangiitis with obstructive pneumonia progressing to hypertrophic pachymeningitis: A case report","volume":"100","author":"Hayashi","year":"2021","journal-title":"Medicine"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e1088","DOI":"10.1097\/MD.0000000000001088","article-title":"Tracheobronchial Stenoses in Granulomatosis With Polyangiitis (Wegener\u2019s): A Report on 26 Cases","volume":"94","author":"Girard","year":"2015","journal-title":"Medicine"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1097\/MD.0000000000000229","article-title":"Prolonged B Cell Depletion With Rituximab is Effective in Treating Refractory Pulmonary Granulomatous Inflammation in Granulomatosis With Polyangiitis (GPA)","volume":"93","author":"Henderson","year":"2014","journal-title":"Medicine"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e2220925","DOI":"10.1001\/jamanetworkopen.2022.20925","article-title":"Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","volume":"5","author":"Thietart","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/17843286.2019.1578041","article-title":"Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort","volume":"75","author":"Chasseur","year":"2020","journal-title":"Acta Clin. Belg."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"608942","DOI":"10.5402\/2011\/608942","article-title":"Wegener\u2019s Granulomatosis Presenting with Pachymeningitis: Clinical and Imaging Remission by Rituximab","volume":"2011","author":"Just","year":"2011","journal-title":"ISRN Rheumatol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00467-012-2332-4","article-title":"Late recovery of renal function by rituximab in a patient with Wegener\u2019s granulomatosis","volume":"28","author":"Malina","year":"2013","journal-title":"Pediatr. Nephrol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/tri.12203","article-title":"Rituximab for remission induction in recurrent ANCA-associated glomerulonephritis postkidney transplant","volume":"26","author":"Murakami","year":"2013","journal-title":"Transpl. Int."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.4158\/EP12181.CR","article-title":"Refractory pituitary granulomatosis with polyangiitis (Wegener\u2019s) treated with rituximab","volume":"19","author":"Hughes","year":"2013","journal-title":"Endocr. Pract."},{"key":"ref_150","first-page":"S138","article-title":"Granulomatosis with polyangiitis presenting as a renal mass successfully treated with rituximab","volume":"32","author":"Bajocchi","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/MAJ.0000000000000536","article-title":"Granulomatosis With Polyangiitis Presenting as Gastric Ulcer: An Unusual Initial Manifestation Successfully Treated With Rituximab","volume":"350","author":"Malik","year":"2015","journal-title":"Am. J. Med. Sci."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1111\/1756-185X.12850","article-title":"Successful treatment of PR3-ANCA positive vasculitis with pancreatitis as the first manifestation with rituximab","volume":"20","author":"Yilmaz","year":"2017","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_153","first-page":"74","article-title":"Good response to rituximab in a patient with granulomatosis with polyangiitis and pulmonary, renal manifestations and ophthalmoplegia","volume":"41","author":"Pantoja","year":"2016","journal-title":"Acta Reumatol. Port."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/RHU.0000000000000447","article-title":"Extensive Pyoderma Gangrenosum Associated with Granulomatosis with Polyangiitis with Both Responsive to Rituximab","volume":"22","author":"Murthy","year":"2016","journal-title":"J. Clin. Rheumatol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/1756-185X.12274","article-title":"A case of granulomatosis with polyangiitis and pyoderma gangrenosum successfully treated with infliximab and rituximab","volume":"17","author":"Donmez","year":"2014","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1111\/1756-185X.12882","article-title":"Successful treatment of large refractory pyoderma gangrenosum-like presentation of granulomatosis with polyangiitis by rituximab","volume":"20","author":"Sen","year":"2017","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_157","first-page":"bcr-2018","article-title":"Prostatitis, a rare presentation of granulomatosis with polyangiitis, successfully treated with rituximab and prednisone","volume":"2018","author":"Shaukat","year":"2018","journal-title":"BMJ Case Rep."},{"key":"ref_158","first-page":"144","article-title":"Successful use of rituximab in granulomatosis with polyangiitis with aortic inflammation","volume":"37","author":"Bitencourt","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"e230355","DOI":"10.1136\/bcr-2019-230355","article-title":"Granulomatosis with polyangiitis with intestinal involvement successfully treated with rituximab and surgery","volume":"12","author":"Sato","year":"2019","journal-title":"BMJ Case Rep."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5606\/ArchRheumatol.2019.6960","article-title":"Treating Granulomatosis With Polyangiitis Presenting as Mastitis With Rituximab","volume":"34","author":"Ali","year":"2018","journal-title":"Arch. Rheumatol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s00296-019-04343-3","article-title":"Aortitis caused by antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: A case-based review","volume":"39","author":"Skeik","year":"2019","journal-title":"Rheumatol. Int."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez, I.A., Friesen, R., McGaw, T., and Levin, L. (2021). Granulomatosis With Polyangiitis Mistaken as a Temporomandibular Joint Disorder: A Case Report. Clin. Adv. Periodontics.","DOI":"10.1002\/cap.10189"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/j.chest.2020.06.022","article-title":"Successful Induction Treatment With Rituximab of Isolated Pauci-Immune Pulmonary Capillaritis Presenting as Diffuse Alveolar Hemorrhage in a Pediatric Patient","volume":"158","author":"Lewinter","year":"2020","journal-title":"Chest"},{"key":"ref_164","first-page":"258","article-title":"Granulomatosis with polyangiitis with isolated orbital involvement in children: A case report successfully treated with Rituximab and review of literature","volume":"44","year":"2019","journal-title":"Acta Reumatol. Port."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2169\/internalmedicine.4881-20","article-title":"Successful Treatment with Rituximab for Granulomatosis with Polyangiitis and Multiple Cranial Neuropathies","volume":"60","author":"Horiuchi","year":"2021","journal-title":"Intern. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.4103\/ijo.IJO_2249_19","article-title":"Rituximab therapy combined with methotrexate for severe necrotizing scleritis in a case of granulomatosis with polyangiitis","volume":"68","author":"Murthy","year":"2020","journal-title":"Indian J. Ophthalmol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/imj.15224","article-title":"Granulomatosis with polyangiitis complicated by genital involvement: Sustained response to rituximab","volume":"51","author":"Paxton","year":"2021","journal-title":"Intern. Med. J."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.2169\/internalmedicine.6541-20","article-title":"Subcutaneous Cheek Nodule Associated with Granulomatosis with Polyangiitis","volume":"60","author":"Hayashi","year":"2021","journal-title":"Intern. Med."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e13479","DOI":"10.1111\/dth.13479","article-title":"Response to rituximab of pseudotumoral digital nodules in a patient with granulomatosis with polyangiitis with alpha-1 antitrypsin deficiency: A case report","volume":"33","author":"Aitmehdi","year":"2020","journal-title":"Dermatologic. Ther."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/1756-185X.13046","article-title":"Hypertrophic pachymeningitis is a characteristic manifestation of granulomatosis with polyangiitis: A retrospective study of anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"20","author":"Shimojima","year":"2017","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10067-009-1291-z","article-title":"Successful treatment of hypertrophic pachymeningitis in refractory Wegener\u2019s granulomatosis with rituximab","volume":"29","author":"Sharma","year":"2010","journal-title":"Clin. Rheumatol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3899\/jrheum.190569","article-title":"Acute Myocarditis in Patients with Antineutrophil Cytoplasmic Antibody-positive Microscopic Polyangiitis and Receiving Rituximab Therapy","volume":"46","author":"Wang","year":"2019","journal-title":"J. Rheumatol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/cup.13632","article-title":"Granulomatosis with polyangiitis presenting as palpable purpura with sinusitis, hemoptysis, and lung cavitation","volume":"47","author":"Wat","year":"2020","journal-title":"J. Cutan. Pathol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1097\/RHU.0000000000001075","article-title":"Relapsing Primary Central Nervous System Vasculitis Treated With Rituximab","volume":"26","author":"Messmer","year":"2020","journal-title":"J. Clin. Rheumatol."},{"key":"ref_175","first-page":"002448","article-title":"Granulomatosis with Polyangiitis: Recurrence or Treatment Consequences?","volume":"8","author":"Diegues","year":"2021","journal-title":"Eur. J. Case Rep. Intern. Med."},{"key":"ref_176","first-page":"e18197","article-title":"Renal Involvement and Its Treatment in Pediatric Patients With Proteinase-3 Anti-Neutrophil Cytoplasmic Antibody Positive Granulomatosis with Polyangiitis: A Case Series","volume":"13","author":"Wu","year":"2021","journal-title":"Cureus"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ehjcr\/ytaa307","article-title":"Aortic valve replacement due to granulomatosis with polyangiitis: A case series","volume":"4","author":"Uijtterhaegen","year":"2020","journal-title":"Eur. Heart J. Case Rep."},{"key":"ref_178","first-page":"102","article-title":"Granulomatosis with Polyangiitis (GPA) Mimicking Tuberculosis","volume":"65","author":"Haridas","year":"2017","journal-title":"J. Assoc. Physicians India"},{"key":"ref_179","first-page":"S142","article-title":"Successful treatment of gynaecological involvement of granulomatosis with polyangiitis (Wegener\u2019s granulomatosis) by rituximab","volume":"33","author":"Bastone","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"e0824","DOI":"10.1002\/rcr2.824","article-title":"A case of granulomatosis with polyangiitis mimicking lung malignancy","volume":"9","author":"Han","year":"2021","journal-title":"Respirol. Case Rep."},{"key":"ref_181","first-page":"e14205","article-title":"From Kidney to Brain: An Uncommon Severe Relapse of Myeloperoxidase Anti-Neutrophil Cytoplasmic Antibody (MPO-ANCA) Vasculitis","volume":"13","author":"Maia","year":"2021","journal-title":"Cureus"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"101902","DOI":"10.1016\/j.eucr.2021.101902","article-title":"Leukocytoclastic vasculitis leading to penile necrosis and ischemia of the bladder and urethra","volume":"40","author":"Moseley","year":"2022","journal-title":"Urol. Case Rep."},{"key":"ref_183","first-page":"e25445","article-title":"Cytoplasmic Antineutrophil Cytoplasmic Antibodies (C-ANCA) Vasculitis: An Uncommon Complication After Stem Cell Transplantation","volume":"14","author":"Raja","year":"2022","journal-title":"Cureus"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1159\/000518971","article-title":"Initial Presentation of Granulomatosis with Polyangiitis as Progressive Skull Base Osteomyelitis","volume":"84","author":"Qureshi","year":"2022","journal-title":"ORL J. Otorhinolaryngol. Relat. Spec."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s13256-022-03492-7","article-title":"Granulomatosis with polyangiitis in a patient with polydipsia, facial nerve paralysis, and severe otologic complaints: A case report and review of the literature","volume":"16","author":"Koenen","year":"2022","journal-title":"J. Med. Case Rep."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1620\/tjem.2022.J053","article-title":"Presence of Phlebitis in Aseptic Nasal Septal Abscess Complicated with Ulcerative Colitis; Possible Association with Granulomatosis with Polyangiitis: A Case Report","volume":"258","author":"Ishikawa","year":"2022","journal-title":"Tohoku J. Exp. Med."},{"key":"ref_187","first-page":"2737242","article-title":"Oral and Lower Extremity Ulcers as the Initial Presentation of Granulomatosis with Polyangiitis","volume":"2022","author":"Dominguez","year":"2022","journal-title":"Case Rep. Med."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2169\/internalmedicine.4752-20","article-title":"Membranous Nephropathy with Proteinase 3-ANCA-associated Vasculitis Successfully Treated with Rituximab","volume":"60","author":"Yoshida","year":"2021","journal-title":"Intern. Med."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"158","DOI":"10.47391\/JPMA.11-1701","article-title":"Role of Rituximab in miraculous cessation of ventricular tachycardia in Granulomatosis with polyangiitis: A case report","volume":"72","author":"Sultan","year":"2022","journal-title":"J. Pak. Med. Assoc."},{"key":"ref_190","first-page":"e24132","article-title":"Hydralazine-Induced Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: A Case Report and Literature Review","volume":"14","author":"Alawneh","year":"2022","journal-title":"Cureus"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1573397116666200517120935","article-title":"Fatal Outcome of Rituximab in an ANCA Negative Granulomatosis with Polyangiitis Patient with Acute Pancreatitis and Pancreatic Mass","volume":"17","author":"Alesaeidi","year":"2021","journal-title":"Curr. Rheumatol. Rev."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1080\/08923973.2020.1717526","article-title":"Paradoxical reaction to rituximab in patients with pemphigus: A report of 10 cases","volume":"42","author":"Nili","year":"2020","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.intimp.2019.02.037","article-title":"Unexpected worsening of pemphigus vulgaris after rituximab: A report of three cases","volume":"71","author":"Mahmoudi","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2174\/1573397117666210219121659","article-title":"The Paradoxical Reaction to Rituximab in Six Granulomatosis with Polyangiitis Patients: How Could it be Explained and Managed?","volume":"17","author":"Alesaeidi","year":"2021","journal-title":"Curr. Rheumatol. Rev."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.4103\/ijo.IJO_1644_20","article-title":"Worsening of posterior scleritis and orbital pseudotumor in a patient with granulomatosis polyangiitis with rituximab-A case report","volume":"68","author":"Babu","year":"2020","journal-title":"Indian J. Ophthalmol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/j.jcjo.2018.12.004","article-title":"Ocular and orbital exacerbation after rituximab therapy for granulomatosis with polyangiitis","volume":"54","author":"Shih","year":"2019","journal-title":"Can. J. Ophthalmol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s11307-011-0527-x","article-title":"(99m)Tc-labeled rituximab for imaging B lymphocyte infiltration in inflammatory autoimmune disease patients","volume":"14","author":"Malviya","year":"2012","journal-title":"Mol. Imaging Biol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/cc11304","article-title":"Clinical review: Serious adverse events associated with the use of rituximab\u2014A critical care perspective","volume":"16","author":"Kasi","year":"2012","journal-title":"Crit. Care"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/jamaophthalmol.2013.8179","article-title":"Rituximab therapy for refractory orbital inflammation: Results of a phase 1\/2, dose-ranging, randomized clinical trial","volume":"132","author":"Suhler","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"ref_200","first-page":"279","article-title":"Current and future prospects in the management of granulomatosis with polyangiitis (Wegener\u2019s granulomatosis)","volume":"10","author":"Tarzi","year":"2014","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0161-6420(97)30251-6","article-title":"The clinical and pathologic constellation of Wegener granulomatosis of the orbit","volume":"104","author":"Perry","year":"1997","journal-title":"Ophthalmology"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/j.1755-3768.2008.01179.x","article-title":"Sclerosing Wegener\u2019s granulomatosis in the orbit","volume":"86","author":"Ostri","year":"2008","journal-title":"Acta Ophthalmol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1097\/00005537-200211000-00007","article-title":"Wegener\u2019s granulomatosis of the orbit: A clinicopathological study of 15 patients","volume":"112","author":"Fechner","year":"2002","journal-title":"Laryngoscope"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/art.21650","article-title":"Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: Relationships with B cell depletion, circulating antibodies, and clinical relapse","volume":"54","author":"Cambridge","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"102505","DOI":"10.1016\/j.autrev.2020.102505","article-title":"Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A meta-analysis","volume":"19","author":"Euvrard","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_206","first-page":"538137","article-title":"Fatal cytomegalovirus disease after combination therapy with corticosteroids and rituximab for granulomatosis with polyangiitis","volume":"2015","author":"Hilal","year":"2015","journal-title":"Case. Rep. Rheumatol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3899\/jrheum.121247","article-title":"Infection risks during longterm rituximab therapy change over time","volume":"40","author":"Besada","year":"2013","journal-title":"J. Rheumatol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1002\/acr.24332","article-title":"Long-Term Safety of Rituximab in Granulomatosis with Polyangiitis and in Microscopic Polyangiitis","volume":"73","author":"Merkel","year":"2021","journal-title":"Arthritis Care Res."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.150051","article-title":"Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years","volume":"42","author":"Fleischmann","year":"2015","journal-title":"J. Rheumatol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13075-020-02215-x","article-title":"Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation","volume":"22","author":"Miyazaki","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/rheumatology\/keu452","article-title":"Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis","volume":"54","author":"Alberici","year":"2015","journal-title":"Rheumatology"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/art.40032","article-title":"Effect of Continuous B Cell Depletion with Rituximab on Pathogenic Autoantibodies and Total IgG Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","volume":"69","author":"Cortazar","year":"2017","journal-title":"Arthritis Rheum."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12969-019-0365-y","article-title":"Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases","volume":"17","author":"Khojah","year":"2019","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.3389\/fimmu.2021.760708","article-title":"The Risk of Severe Infections Following Rituximab Administration in Patients With Autoimmune Kidney Diseases: Austrian ABCDE Registry Analysis","volume":"12","author":"Odler","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00296-021-04847-x","article-title":"Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: A single-center retrospective cohort study","volume":"41","author":"Wade","year":"2021","journal-title":"Rheumatol. Int."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"671503","DOI":"10.3389\/fimmu.2021.671503","article-title":"Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease","volume":"12","author":"Tieu","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1093\/rheumatology\/keu194","article-title":"Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis","volume":"53","author":"Besada","year":"2014","journal-title":"Rheumatology"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5152\/eujrheum.2022.20258","article-title":"Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course","volume":"9","author":"Tariq","year":"2022","journal-title":"Eur. J. Rheumatol."},{"key":"ref_219","doi-asserted-by":"crossref","unstructured":"Besada, E. (2016). Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab. BMC Musculoskelet. Disord., 17.","DOI":"10.1186\/s12891-015-0860-3"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1007\/s00296-011-2353-5","article-title":"Sustained hypogammaglobulinemia under rituximab maintenance therapy could increase the risk for serious infections: A report of two cases","volume":"33","author":"Besada","year":"2013","journal-title":"Rheumatol. Int."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s40744-022-00433-0","article-title":"Evaluation of Serious Infection in Pediatric Patients with Low Immunoglobulin Levels Receiving Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis","volume":"9","author":"Melega","year":"2022","journal-title":"Rheumatol. Ther."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/ckj\/sfx014","article-title":"Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"10","author":"Shah","year":"2017","journal-title":"Clin. Kidney J."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3109\/03009742.2012.739638","article-title":"Rituximab for ANCA-associated vasculitis in the setting of severe infection","volume":"42","author":"Gregersen","year":"2013","journal-title":"Scand. J. Rheumatol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/rheumatology\/keab293","article-title":"Severe infections in patients with ANCA-associated vasculitis treated with rituximab","volume":"61","author":"Segelmark","year":"2021","journal-title":"Rheumatology"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000509893","article-title":"Severe Infections following Rituximab Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","volume":"7","author":"Li","year":"2021","journal-title":"Kidney Dis."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3899\/jrheum.090856","article-title":"Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials","volume":"37","author":"Emery","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/annrheumdis-2017-212861","article-title":"Trimethoprim-sulfamethoxazole prophylaxis prevents severe\/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis","volume":"77","author":"Kronbichler","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s00296-012-2587-x","article-title":"Rituximab: Rescue therapy in life-threatening complications or refractory autoimmune diseases: A single center experience","volume":"33","author":"Guralnik","year":"2013","journal-title":"Rheumatol. Int."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/RHU.0b013e31823ee5bf","article-title":"Rituximab associated pneumonitis in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"18","author":"Arulkumaran","year":"2012","journal-title":"J. Clin. Rheumatol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/acr.20279","article-title":"Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener\u2019s granulomatosis","volume":"62","author":"Hugle","year":"2010","journal-title":"Arthritis Care Res."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s10067-013-2293-4","article-title":"Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis?","volume":"32","author":"Besada","year":"2013","journal-title":"Clin. Rheumatol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/ckj\/sfx038","article-title":"Infectious complications of rituximab therapy in renal disease","volume":"10","author":"Nixon","year":"2017","journal-title":"Clin. Kidney J."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/00325481.2019.1667211","article-title":"CMV gastric ulcer in a patient with pauci immune crescentic glomerulonephritis on rituximab\u2014A rare combination","volume":"131","author":"Ishtiaq","year":"2019","journal-title":"Postgrad. Med."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/03009742.2016.1241298","article-title":"Life-threatening rituximab-induced pyoderma gangrenosum successfully treated with intravenous immunoglobulin","volume":"46","author":"Vikse","year":"2017","journal-title":"Scand. J. Rheumatol."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1517\/14712598.2014.912273","article-title":"Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy","volume":"14","author":"Mangia","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_236","doi-asserted-by":"crossref","unstructured":"Ahn, S.S., Han, M., Yoo, J., Jung, S.M., Song, J.J., Park, Y.-B., Jung, I., and Lee, S.-W. (2019). Risk of Cancers in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Results from the Korea National Health Insurance Claims Database 2010\u20132018. J. Clin. Med., 8.","DOI":"10.3390\/jcm8111871"},{"key":"ref_237","doi-asserted-by":"crossref","unstructured":"Shang, W., Ning, Y., Xu, X., Li, M., Guo, S., Han, M., Zeng, R., Ge, S., and Xu, G. (2015). Incidence of Cancer in ANCA-Associated Vasculitis: A Meta-Analysis of Observational Studies. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0126016"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","article-title":"Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis","volume":"76","author":"Rizzo","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.2169\/internalmedicine.0335-17","article-title":"Rituximab-induced Acute Thrombocytopenia in Granulomatosis with Polyangiitis","volume":"57","author":"Endo","year":"2018","journal-title":"Intern. Med."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3109\/03009742.2016.1138318","article-title":"Late-onset neutropenia after rituximab in ANCA-associated vasculitis","volume":"45","author":"Knight","year":"2016","journal-title":"Scand. J. Rheumatol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/art.30427","article-title":"Late-onset neutropenia following rituximab therapy in rheumatic diseases: Association with B lymphocyte depletion and infections","volume":"63","author":"Tesfa","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/art.34468","article-title":"Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies","volume":"64","author":"Molloy","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00296-019-04272-1","article-title":"Tolerability and safety of long-term rituximab treatment in systemic inflammatory and autoimmune diseases","volume":"39","author":"Vikse","year":"2019","journal-title":"Rheumatol. Int."},{"key":"ref_244","doi-asserted-by":"crossref","unstructured":"Yockey, L., Dowst, S., Zonozi, R., Huizenga, N., Murphy, P., Laliberte, K., Rosenthal, J., Niles, J.L., and Mitchell, C.M. (2021). Inflammatory vaginitis in women on long-term rituximab treatment for autoimmune disorders. BMC Women\u2019s Health, 21.","DOI":"10.1186\/s12905-021-01423-0"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.3899\/jrheum.160456","article-title":"Perianal Crohn Disease after Treatment with Rituximab for Active Granulomatosis with Polyangiitis","volume":"43","author":"Fraser","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"e248864","DOI":"10.1136\/bcr-2022-248864","article-title":"Posterior reversible encephalopathy syndrome after first rituximab transfusion for treatment of granulomatosis with polyangiitis","volume":"15","author":"Gong","year":"2022","journal-title":"BMJ Case Rep."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2169\/internalmedicine.7941-21","article-title":"A Young Patient with Microscopic Polyangiitis Requiring Hemodialysis with Complications of Repeated Episodes of Posterior Reversible Encephalopathy Syndrome Probably Due to Different Etiologies","volume":"61","author":"Asakawa","year":"2022","journal-title":"Intern. Med."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/art.39562","article-title":"Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes","volume":"68","author":"Tryfon","year":"2016","journal-title":"Arthritis Rheum."}],"container-title":["Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-7737\/11\/12\/1767\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:34:56Z","timestamp":1760146496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-7737\/11\/12\/1767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":248,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["biology11121767"],"URL":"https:\/\/doi.org\/10.3390\/biology11121767","relation":{},"ISSN":["2079-7737"],"issn-type":[{"value":"2079-7737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,6]]}}}